Dinesh V. Patel - Nov 25, 2024 Form 4 Insider Report for Protagonist Therapeutics, Inc (PTGX)

Role
President and CEO, Director
Signature
/s/ Matthew Gosling, Attorney-in-Fact for Dinesh V. Patel, Ph.D.
Stock symbol
PTGX
Transactions as of
Nov 25, 2024
Transactions value $
-$4,643,481
Form type
4
Date filed
11/27/2024, 07:08 PM
Previous filing
Nov 21, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PTGX Common Stock Sale -$3.69M -78.5K -15.28% $46.96 435K Nov 25, 2024 Direct F1, F2
transaction PTGX Common Stock Gift $0 -7K -1.61% $0.00 428K Nov 25, 2024 Direct F3
transaction PTGX Common Stock Options Exercise $37.3K +1.73K +0.4% $21.58 430K Nov 25, 2024 Direct
transaction PTGX Common Stock Sale -$993K -21.5K -5% $46.25 408K Nov 26, 2024 Direct F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PTGX Stock Option (right to buy) Options Exercise $0 -1.73K -0.54% $0.00 318K Nov 25, 2024 Common Stock 1.73K $21.58 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $46.50 to $47.47. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F2 Includes an aggregate of 313 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on September 9, 2024.
F3 On November 25, 2024, the Reporting Person made a charitable donation of 7,000 shares of common stock to a donor-advised fund, which will use the gifted shares for charitable purposes.
F4 The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $44.49 to $46.50. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F5 These stock options are fully vested.